Overview
Biotech firm Ionis Q4 revenue beat analyst expectations
Adjusted operating income for Q4 beat analyst estimates
Company preparing for multiple product launches in 2026
Outlook
Ionis expects 2026 revenue between $800 mln and $825 mln
Company anticipates operating loss on a non-GAAP basis of $500 mln to $550 mln in 2026
Ionis plans modest increase in non-GAAP operating expenses for 2026
Result Drivers
PRODUCT LAUNCHES - TRYNGOLZA sales increased 56% QoQ, driven by successful launch and EU approval
R&D REVENUE - $280 mln upfront payment from Ono Pharmaceutical for sapablursen licensing boosted revenue
EXPENSES - Increased operating expenses due to commercialization efforts for TRYNGOLZA, DAWNZERA and WAINUA
Company press release: ID:nBw2nfT4Ba
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q4 Revenue | Beat | $203 mln | $156.09 mln (15 Analysts) |
Q4 Adjusted Operating Income | Beat | -$172 mln | -$210.27 mln (13 Analysts) |
Q4 Adjusted Operating Expenses | $375 mln | ||
Q4 Operating Expenses | $418 mln | ||
Q4 Operating Income | -$215 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ionis Pharmaceuticals Inc is $95.00, about 11.2% above its February 24 closing price of $85.45
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Comments